Cargando…
Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives
Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) has rarely been used in the field of therapeutic drug monitoring, partly because of the complexity of the ionization processes between the compounds to be quantified and the many MALDI matrices available. The development of a v...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956427/ https://www.ncbi.nlm.nih.gov/pubmed/33652935 http://dx.doi.org/10.3390/molecules26051281 |
_version_ | 1783664432890511360 |
---|---|
author | Fresnais, Margaux Yildirim, Esra Karabulut, Seda Jäger, Dirk Zörnig, Inka Benzel, Julia Pajtler, Kristian W. Pfister, Stefan M. Burhenne, Jürgen Haefeli, Walter E. Longuespée, Rémi |
author_facet | Fresnais, Margaux Yildirim, Esra Karabulut, Seda Jäger, Dirk Zörnig, Inka Benzel, Julia Pajtler, Kristian W. Pfister, Stefan M. Burhenne, Jürgen Haefeli, Walter E. Longuespée, Rémi |
author_sort | Fresnais, Margaux |
collection | PubMed |
description | Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) has rarely been used in the field of therapeutic drug monitoring, partly because of the complexity of the ionization processes between the compounds to be quantified and the many MALDI matrices available. The development of a viable MALDI-MS method that meets regulatory guidelines for bioanalytical method validation requires prior knowledge of the suitability of (i) the MALDI matrix with the analyte class and properties for ionization, (ii) the crystallization properties of the MALDI matrix with automation features, and (iii) the MS instrumentation used to achieve sensitive and specific measurements in order to determine low pharmacological drug concentrations in biological matrices. In the present hybrid article/white paper, we review the developments required for the establishment of MALDI-MS assays for the quantification of drugs in tissues and plasma, illustrated with concrete results for the different steps. We summarize the necessary parameters that need to be controlled for the successful development of fully validated MALDI-MS methods according to regulatory authorities, as well as currently unsolved problems and promising ways to address them. Finally, we propose an expert opinion on future perspectives and needs in order to establish MALDI-MS as a universal method for therapeutic drug monitoring. |
format | Online Article Text |
id | pubmed-7956427 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79564272021-03-16 Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives Fresnais, Margaux Yildirim, Esra Karabulut, Seda Jäger, Dirk Zörnig, Inka Benzel, Julia Pajtler, Kristian W. Pfister, Stefan M. Burhenne, Jürgen Haefeli, Walter E. Longuespée, Rémi Molecules Article Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) has rarely been used in the field of therapeutic drug monitoring, partly because of the complexity of the ionization processes between the compounds to be quantified and the many MALDI matrices available. The development of a viable MALDI-MS method that meets regulatory guidelines for bioanalytical method validation requires prior knowledge of the suitability of (i) the MALDI matrix with the analyte class and properties for ionization, (ii) the crystallization properties of the MALDI matrix with automation features, and (iii) the MS instrumentation used to achieve sensitive and specific measurements in order to determine low pharmacological drug concentrations in biological matrices. In the present hybrid article/white paper, we review the developments required for the establishment of MALDI-MS assays for the quantification of drugs in tissues and plasma, illustrated with concrete results for the different steps. We summarize the necessary parameters that need to be controlled for the successful development of fully validated MALDI-MS methods according to regulatory authorities, as well as currently unsolved problems and promising ways to address them. Finally, we propose an expert opinion on future perspectives and needs in order to establish MALDI-MS as a universal method for therapeutic drug monitoring. MDPI 2021-02-26 /pmc/articles/PMC7956427/ /pubmed/33652935 http://dx.doi.org/10.3390/molecules26051281 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fresnais, Margaux Yildirim, Esra Karabulut, Seda Jäger, Dirk Zörnig, Inka Benzel, Julia Pajtler, Kristian W. Pfister, Stefan M. Burhenne, Jürgen Haefeli, Walter E. Longuespée, Rémi Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives |
title | Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives |
title_full | Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives |
title_fullStr | Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives |
title_full_unstemmed | Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives |
title_short | Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives |
title_sort | rapid maldi-ms assays for drug quantification in biological matrices: lessons learned, new developments, and future perspectives |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956427/ https://www.ncbi.nlm.nih.gov/pubmed/33652935 http://dx.doi.org/10.3390/molecules26051281 |
work_keys_str_mv | AT fresnaismargaux rapidmaldimsassaysfordrugquantificationinbiologicalmatriceslessonslearnednewdevelopmentsandfutureperspectives AT yildirimesra rapidmaldimsassaysfordrugquantificationinbiologicalmatriceslessonslearnednewdevelopmentsandfutureperspectives AT karabulutseda rapidmaldimsassaysfordrugquantificationinbiologicalmatriceslessonslearnednewdevelopmentsandfutureperspectives AT jagerdirk rapidmaldimsassaysfordrugquantificationinbiologicalmatriceslessonslearnednewdevelopmentsandfutureperspectives AT zorniginka rapidmaldimsassaysfordrugquantificationinbiologicalmatriceslessonslearnednewdevelopmentsandfutureperspectives AT benzeljulia rapidmaldimsassaysfordrugquantificationinbiologicalmatriceslessonslearnednewdevelopmentsandfutureperspectives AT pajtlerkristianw rapidmaldimsassaysfordrugquantificationinbiologicalmatriceslessonslearnednewdevelopmentsandfutureperspectives AT pfisterstefanm rapidmaldimsassaysfordrugquantificationinbiologicalmatriceslessonslearnednewdevelopmentsandfutureperspectives AT burhennejurgen rapidmaldimsassaysfordrugquantificationinbiologicalmatriceslessonslearnednewdevelopmentsandfutureperspectives AT haefeliwaltere rapidmaldimsassaysfordrugquantificationinbiologicalmatriceslessonslearnednewdevelopmentsandfutureperspectives AT longuespeeremi rapidmaldimsassaysfordrugquantificationinbiologicalmatriceslessonslearnednewdevelopmentsandfutureperspectives |